Kristeleit, Rebecca S
University College London
3 papers on CoChatORCID 0000-0003-3825-1326
Most cited papers
- Verified
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology
PARP inhibition in cancer therapyBRCA gene mutations in cancer
Cited by 1,196
- Verified
Homologous recombination deficiency and ovarian cancer
Ledermann, J. A., Drew, Y., & Kristeleit, R. S. (2016) · European Journal of Cancer
PARP inhibition in cancer therapyBRCA gene mutations in cancer
Cited by 258
- Verified
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer
Marth, C., Vergote, I., Scambia, G., Oberaigner, W., Clamp, A., Berger, R., Kurzeder, C., Colombo, N., Vuylsteke, P., Lorusso, D., et al. (2017) · European Journal of Cancer
Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapy
Cited by 79
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free